Simeon is CEO and Managing Partner of SR One. Simeon co-founded SR One Capital Management following its spin-out from GSK in 2020. Previously, he worked in management consulting (Bain & Co.) and investment banking (Goldman Sachs). Simeon led SR One’s investments in several marquee deals including CRISPR Therapeutics (CRSP), Principia Biopharma (PRNB), Turning Point Therapeutics (TPTX), Progyny (PGNY), and he co-founded both Nkarta Therapeutics (NKTX) and Arcellx (ACLX).
Simeon has a BA from the Johns Hopkins University and an MD/MBA from the University of Pennsylvania School of Medicine/The Wharton School.
At SR One we seek to partner with founders and entrepreneurs whose ambition is to rewrite the medical textbooks across a wide range of disease areas and modalities.